InvestSMART

Clinuvel Pharmaceuticals Limited (ASX: CUV) - Announcements

Current share price for CUV : $7.180 0.02 (0.28%)+

ASX company news and announcements for Clinuvel Pharmaceuticals Limited (CUV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clinuvel Pharmaceuticals Limited (CUV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clinuvel Pharmaceuticals Limited (CUV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clinuvel Pharmaceuticals Limited (CUV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$362 Appendix 4C - quarterly 17 Apr 2014 8:29AM $1.630 $7.180 risen by 340.49%
$362 Half Yearly Report and Accounts 26 Feb 2014 10:43AM $1.550 $7.180 risen by 363.23%
$362 Phase II study starts in skin disorder Hailey-Hailey Disease 10 Feb 2014 10:25AM $1.450 $7.180 risen by 395.17%
$362 Appendix 4C - quarterly 31 Jan 2014 8:35AM $1.415 $7.180 risen by 407.42%
$362 EMA review of SCENESSE extended to mid-2014 30 Jan 2014 10:08AM $1.200 $7.180 risen by 498.33%
$362 Media Release- Clinuvel successful in US Phase III trial 11 Nov 2013 9:46AM $1.500 $7.180 risen by 378.67%
$362 Clinical significance and benefit from SCENESSE in US Phase 11 Nov 2013 9:38AM $1.500 $7.180 risen by 378.67%
$362 Clinuvel to start a Phase II vitiligo study in Singapore 4 Nov 2013 9:40AM $1.500 $7.180 risen by 378.67%
$362 Appendix 4C - quarterly 28 Oct 2013 9:17AM $1.570 $7.180 risen by 357.32%
$362 Five month study follow up - SCENESSE in vitiligo (CUV102) 2 Sep 2013 9:05AM $1.795 $7.180 risen by 300%
$362 Preliminary Final Report 28 Aug 2013 3:23PM $1.730 $7.180 risen by 315.03%
$362 Appendix 4C - quarterly 31 Jul 2013 8:28AM $1.900 $7.180 risen by 277.89%
$362 Reinstatement to Official Quotation 6 May 2013 9:45AM $2.100 $7.180 risen by 241.90%
$362 Placement 6 May 2013 9:45AM $2.100 $7.180 risen by 241.90%
$362 Suspension from Official Quotation 3 May 2013 9:59AM $1.850 $7.180 risen by 288.11%
$362 Trading Halt 1 May 2013 9:56AM $1.850 $7.180 risen by 288.11%
$362 Appendix 4C - quarterly 24 Apr 2013 9:15AM $2.000 $7.180 risen by 259%
$362 Clinuvel clears EMA manufacturing audit 28 Feb 2013 9:07AM $2.400 $7.180 risen by 199.17%
$362 Half Yearly Report and Accounts 27 Feb 2013 1:48PM $2.400 $7.180 risen by 199.17%
$362 Appendix 4C - quarterly 21 Jan 2013 12:00PM $2.220 $7.180 risen by 223.42%
$362 SCENESSE successful in Phase IIa vitiligo study 19 Dec 2012 9:36AM $1.980 $7.180 risen by 262.63%
$362 Appendix 4C - quarterly 22 Oct 2012 10:25AM $1.570 $7.180 risen by 357.32%
$362 Observations from Clinuvel's US vitiligo study published 16 Oct 2012 10:01AM $1.610 $7.180 risen by 345.96%
$362 Management change and regulatory review update 1 Oct 2012 8:47AM $1.560 $7.180 risen by 360.26%
$362 Preliminary Final Report 29 Aug 2012 2:56PM $1.630 $7.180 risen by 340.49%

726 - 750 of 881 results

Page 30 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.